Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function

Author:

Leroy A1,Fillastre J P1,Humbert G1

Affiliation:

1. Department of Biochemistry, University of Rouen, Hôpital Charles Nicolle, France.

Abstract

Lomefloxacin pharmacokinetics were investigated in 6 normal subjects and 24 uremic patients after a single oral dose of 400 mg. In subjects with normal renal function, the peak level in plasma averaged 3.5 +/- 0.9 micrograms/ml (mean +/- standard deviation) and was obtained at 1.3 +/- 0.9 h. The absorption rate constant was 3.8 +/- 1.6 h-1. The terminal half-life was 7.77 +/- 0.95 h. The apparent volume of distribution was 2.54 +/- 0.66 liters/kg. Total body and renal clearances were 259 +/- 83 and 200 +/- 55 ml/min per 1.73 m2, respectively. The percentage of the dose recovered unchanged in 48-h urine was 80.6 +/- 2.8. In uremic patients, the terminal half-life increased in relation to the degree of renal failure: from 8 h in normal subjects to 38 h in severely uremic patients (glomerular filtration rate, less than 10 ml/min). Renal insufficiency did not significantly modify the peak level in plasma, the time to peak, the apparent volume of distribution, or the nonrenal clearance of lomefloxacin. The dialysis clearance of lomefloxacin was 54 +/- 13 ml/min. Linear relationships were found between lomefloxacin pharmacokinetic parameters and glomerular filtration rate data. Dosage adjustments are necessary in uremic patients.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference9 articles.

1. Statistical estimations in pharmacokinetics;Boxenbaum H. G.;J. Pharmacokinet. Biopharm.,1974

2. Ofloxacin pharmacokinetics in renal failure;Filiastre J. P.;Antimicrob. Agents Chemother.,1987

3. Gotch F. A. 1976. Hemodialysis: technical and kinetic considerations p. 1672-1704. In B. M. Brenner and F. C. Rector (ed.) The kidney. The W. B. Saunders Co. Philadelphia.

4. Clinical pharmacokinetics;Greenblatt D. J.;N. Engl. J. Med.,1975

5. In vitro and in vivo activity of NY-198, a new difluorinated quinolone;Hirose T.;Antimicrob. Agents Chemother.,1987

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3